Cancer Immunology Community Seeks Better End Points
November 29, 2016
Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
Continue reading here.
Circulating biomarkers are quickly becoming a crucial part of diagnosis and disease monitoring for physicians, researchers — and even some consumers.
Zebras and giraffes offer one another protection without food competition.